SCHEMBL1961686

SCHEMBL1961686

COC(=O)c1sc(C#CC(C)(C)C)cc1N(C(=O)c1ccc(Cl)cc1Cl)C1CCN(C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 2/20 0.39
▸ CACNA2D1 P54289 2/20 0.36
▸ OPRM1 P35372 1/20 0.36
▸ CYP2E1 P05181 1/20 0.35
▸ PDK2 Q15119 1/20 0.35
▸ NPY1R P25929 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ CNR1 P21554 2/20 0.34
▸ CNR2 P34972 2/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ RAB9A P51151 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ HTR1D P28221 1/20 0.33
▸ HTR1F P30939 1/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ CDK4 P11802 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14982007 0.91 NR1I2 (0.47) NR1I2CACNA2D1OPRM1CYP2E1PDK2
Hydrochloric Acid SCHEMBL1961448 0.90 NR1I2 (0.47) NR1I2CACNA2D1OPRM1CYP2E1PDK2
SCHEMBL1960202 0.89 CYP2E1 (0.39) NR1I2CYP2E1CYP1A2CYP2C19ALDH1A1
SCHEMBL15130688 0.85 NR1I2 (0.56) NR1I2CYP2E1NPY1RCYP1A2CYP2C19
SCHEMBL1961431 0.84 CACNA2D1 (0.41) CACNA2D1OPRM1NPY1RCYP1A2CYP2C19
SCHEMBL15130760 0.84 NR1I2 (0.53) NR1I2CYP2E1NPY1RCYP1A2CYP2C19
SCHEMBL1963185 0.83 NR1I2 (0.45) NR1I2CYP2E1PDK2NPY1RALDH1A1
SCHEMBL14982018 0.83 NR1I2 (0.47) NR1I2CACNA2D1OPRM1CYP2E1PDK2
SCHEMBL1958434 0.82 NR1I2 (0.47) NR1I2CYP2E1PDK2NPY1RALDH1A1
SCHEMBL15130694 0.82 NR1I2 (0.44) NR1I2CYP2E1CYP1A2CYP2C19CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
EP-2504329-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2012-10-03 — — EP disclosed
WO-2011068715-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS HAVCR2, GTF3C3, ZC3HAV1 NR1I2 312/4885CACNA2D1 4872/4885OPRM1 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback